AZD4144 is an orally active NLRP3 inhibitor (EC50: 0.082 µM). AZD4144 effectively inhibits the release of IL-1beta when NLRP3 is overactivated, exerting an anti-inflammatory effect. AZD4144 has low inhibitory effect on hERG and low cardiotoxicity. AZD4144 has the potential to study diseases and conditions associated with NLRP3 inflammasome activation[1].